$VRNA pressing on resistance here at $7.30.. Perceptive Advisors just bought a big chunk of shares - OrbiMed here too, looks ready for a breakout.. lots of upside potential upcoming catalysts and cash position.. sounds like relatively low risk of dilution for the time being. We believe ensifentrine, with its novel mechanism of action, has the potential to benefit patients suffering from COVID-19. Results are anticipated in the first half of 2021. "Also during the third quarter, we initiated the second, multiple dose part of a Phase 2 study with the pMDI formulation of ensifentrine in COPD, which was postponed due to the pandemic. Results are expected in the first half of 2021. "This clinical progress is supported by the $200 million raise we completed in July and we appreciate the highly experienced life science investors that participated in the offering. The funds are expected to support our operations and Phase 3 clinical programs into 2023."